The well-established benefits of neurostimulation have made this industry one of the fastest-growing disciplines within the field of medical technology. We are excited about the vast potential – and we are proud to be in the ideal position to innovate in this largely untapped market, which is at less than 10% penetration as of 2012.
Neurostimulation is expected to grow due to numerous factors, including:
Projected Neurostimulation Market Growth
*QiG internal estimates
The 2012 neurostimulation market is estimated to reach $2.6B (excluding cochlear, drug pumps and external stimulation), and is forecast to grow considerably in the next few years; experts predict a compounded annual growth rate across all neurostimulation markets of 15%, which would result in an estimated market size of $4.5B by 2016.
Spinal Cord Stimulation (SCS) – these systems treat neuropathic pain by delivering electrical current to the spinal cord.
Deep Brain Stimulation (DBS) – these systems deliver electrical stimulation to either inhibit or excite specific nerve signals, thereby offering relief for certain neurological disorders.
Sacral Nerve Stimulation (SNS) – by delivering low-amplitude electrical stimulation to the sacral nerve roots, these systems help treat pelvic dysfunction.
Vagus Nerve Stimulation (VNS) – in these systems, leads are implanted around the vagal nerve in the neck.